Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK11 | Q15759 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | LPO | P22079 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18714610 | 0.89 | KMT2A (0.50) | MAPK11MAPK14KDM4EALDH1A1HPGD | |
| SCHEMBL2116459 | 0.87 | TFPI2 (0.47) | MAPK11MAPK14KDM4EALDH1A1HPGD | |
| SCHEMBL2117935 | 0.86 | MAPK11 (0.48) | MAPK11MAPK14KDM4EALDH1A1HPGD | |
| SCHEMBL423280 | 0.85 | KDM4E (0.42) | MAPK11MAPK14KDM4EALDH1A1HPGD | |
| SCHEMBL12531335 | 0.84 | MAPK11 (0.47) | MAPK11MAPK14KDM4EALDH1A1HPGD | |
| SCHEMBL2117444 | 0.84 | OXER1 (0.55) | MAPK11MAPK14KDM4EALDH1A1HPGD | |
| SCHEMBL1752188 | 0.83 | MAPK11 (0.57) | MAPK11MAPK14KDM4EALDH1A1HPGD | |
| SCHEMBL2117429 | 0.83 | MTNR1A (0.51) | MAPK11MAPK14KDM4EALDH1A1HPGD | |
| SCHEMBL12529413 | 0.82 | MAPK11 (0.46) | MAPK11MAPK14KDM4EALDH1A1HPGD | |
| SCHEMBL10193516 | 0.81 | BUB1 (0.40) | KDM4EALDH1A1HPGDHSD17B10TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123326-A1 | ALLOSTERIC BINDING COMPOUNDS | REGION MIDTJYLLAND (DK) | 2013-05-16 | — | — | US | claimed |
| US-20120095048-A1 | ALLOSTERIC BINDING COMPOUNDS | REGION MIDT JYLLAND (DK) | 2012-04-19 | — | — | US | claimed |
| EP-2398760-A1 | ALLOSTERIC BINDING COMPOUNDS | Aarhus Universitet (DK) | 2011-12-28 | — | — | EP | claimed |
| WO-2010094289-A1 | ALLOSTERIC BINDING COMPOUNDS | AARHUS UNIVERSITET (DK) | 2010-08-26 | — | — | WO | claimed |
| US-20130123326-A1 | ALLOSTERIC BINDING COMPOUNDS | REGION MIDTJYLLAND (DK) | 2013-05-16 | — | — | US | disclosed |
| US-20130123326-A1 | ALLOSTERIC BINDING COMPOUNDS | REGION MIDTJYLLAND (DK) | 2013-05-16 | — | — | US | disclosed |
| US-20130123326-A1 | ALLOSTERIC BINDING COMPOUNDS | REGION MIDTJYLLAND (DK) | 2013-05-16 | — | — | US | disclosed |
| US-8404689-B2 | Heterocyclic amide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120095048-A1 | ALLOSTERIC BINDING COMPOUNDS | REGION MIDT JYLLAND (DK) | 2012-04-19 | — | — | US | disclosed |
| US-20120095048-A1 | ALLOSTERIC BINDING COMPOUNDS | REGION MIDT JYLLAND (DK) | 2012-04-19 | — | — | US | disclosed |
| US-20120095048-A1 | ALLOSTERIC BINDING COMPOUNDS | REGION MIDT JYLLAND (DK) | 2012-04-19 | — | — | US | disclosed |
| EP-2398760-A1 | ALLOSTERIC BINDING COMPOUNDS | Aarhus Universitet (DK) | 2011-12-28 | — | — | EP | disclosed |
| WO-2010094289-A1 | ALLOSTERIC BINDING COMPOUNDS | AARHUS UNIVERSITET (DK) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010094289-A1 | ALLOSTERIC BINDING COMPOUNDS | AARHUS UNIVERSITET (DK) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095048-A1 | ALLOSTERIC BINDING COMPOUNDS | GRIN2C, GRM2, GRIN2B | MAPK11 1129/4885MAPK14 1944/4885KDM4E 2005/4885 |
| US-20130123326-A1 | ALLOSTERIC BINDING COMPOUNDS | GRIN2C, GRM2, GRIN2B | MAPK11 1129/4885MAPK14 1944/4885KDM4E 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.